Metabolism - Clinical and Experimental
Volume 55, Issue 3 , Pages 292-299, March 2006

Stigmasterol reduces plasma cholesterol levels and inhibits hepatic synthesis and intestinal absorption in the rat

  • Ashok K. Batta

      Affiliations

    • Department of Medicine, UMDNJ-NJ Medical School, Newark, NJ 07103, USA
    • Department of Veterans Affairs, NJ Health Care System, East Orange, NJ 07018, USA
    • Corresponding Author InformationCorresponding author. GI Section (15A), VA Medical Center, East Orange, NJ 07019, USA. Tel.: +1 201 676 1000/2289; fax: +1 201 676 2991.
  • ,
  • Guorong Xu

      Affiliations

    • Department of Medicine, UMDNJ-NJ Medical School, Newark, NJ 07103, USA
    • Department of Veterans Affairs, NJ Health Care System, East Orange, NJ 07018, USA
  • ,
  • Akira Honda

      Affiliations

    • Division of Gastroenterology and Hepatology, Ibaraki Prefectural Institute of Public Health and University of Tsukuba, Mito, Ibaraki 310-0852, Japan
  • ,
  • Teruo Miyazaki

      Affiliations

    • Division of Gastroenterology and Hepatology, Ibaraki Prefectural Institute of Public Health and University of Tsukuba, Mito, Ibaraki 310-0852, Japan
  • ,
  • Gerald Salen

      Affiliations

    • Department of Medicine, UMDNJ-NJ Medical School, Newark, NJ 07103, USA

Received 1 July 2005; accepted 5 August 2005.

Abstract 

Plant sterols compete with cholesterol (cholest-5-en-3β-ol) for intestinal absorption to limit absorption and lower plasma concentrations of cholesterol. Stigmasterol (24-ethyl-cholesta-5,22-dien-3β-ol; Δ22 derivative of sitosterol [24-ethyl-cholest-5-en-3β-ol]), but not campesterol (24-methyl-cholest-5-en-3β-ol) and sitosterol, is reported to inhibit cholesterol biosynthesis via inhibition of sterol Δ24-reductase in human Caco-2 and HL-60 cell lines. We studied the effect of feeding 0.5% stigmasterol on plasma and liver sterols and intestinal cholesterol and sitosterol absorption in 12 wild-type Kyoto (WKY) and 12 Wistar rats. After 3 weeks of feeding, cholesterol and sitosterol absorption was determined in 6 rats from each group by plasma dual-isotope ratio method. After 3 more weeks, plasma and hepatic sterols and hepatic enzyme activities were determined in all rats. After feeding stigmasterol, baseline plasma cholesterol was 1.3 times and plant sterols 3 times greater in WKY compared with Wistar rats. Stigmasterol feeding lowered plasma cholesterol by approximately 11%, whereas plasma campesterol and sitosterol levels were virtually unchanged in both rat strains, and stigmasterol constituted 3.2% of plasma sterols in WKY rats and 1% in Wistar rats. After 6 weeks of feeding, cholesterol and sitosterol absorption decreased 23% and 30%, respectively, in WKY, and 22% and 16%, respectively, in the Wistar rats as compared with untreated rats. The intestinal bacteria in both rat strains metabolized stigmasterol to mainly the 5β-H stanol (>40%), with only small amounts of 5α-H derivative (approximately 1.5%), whereas the C-22 double bond was resistant to bacterial metabolism. Hepatic stigmasterol levels increased from 11 μg/g liver tissue to 104 μg/g in WKY rats and from 5 μg/g liver tissue to 21 μg/g in Wistar rats. 3-Hydroxy-3-methylglutaryl coenzyme A reductase activity was suppressed 4-fold in the WKY and almost 1.8-fold in Wistar rats, cholesterol 7α-hydroxylase activity was suppressed 1.6-fold in the WKY and 3.5-fold in Wistar rats, whereas cholesterol 27-hydroxylase activity was unchanged after feeding. In conclusion, stigmasterol, when fed, lowers plasma cholesterol levels, inhibits intestinal cholesterol and plant sterol absorption, and suppresses hepatic cholesterol and classic bile acid synthesis in Wistar as well as WKY rats. However, plasma and hepatic incorporation of stigmasterol is low.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0026-0495(05)00348-3

doi:10.1016/j.metabol.2005.08.024

Metabolism - Clinical and Experimental
Volume 55, Issue 3 , Pages 292-299, March 2006